Members present: Mark Danielsen, Mary Ann Dutton, Daniel Djakiew, Carolyn Ecelbarger, Rebecca Evangelista, Robert Glazer, George Luta, Eileen Moore, Prosper N’Gouemo, Cesar Santos, Miriam Toporowicz, Scott Turner, Rhonda Friedman

Members absent: Christine Colie, Ken Tercyak, Ladan Eshkevari, Karen Gale, Maria Luisa Marquez, Pamella Saunders, Andrea Singer, Vanessa Sheppard,

Guests:
Jett McCann, Bob Clarke, Irene Jillson, Dan Merenstein

Agenda
1. Approval of the minutes from November
2. Presentation of bridge funding mechanisms within BGRO (Robert Clarke)
3. Old business (Budget oversight committee, Executive committee, salary issues)
4. New business (Senate Election, agendas for the February and March caucus meetings)

Minutes (Robert Glazer)

The meeting was called to order at 12:02 pm by Mark Danielsen.

1) The minutes for November were approved

2) Presentation by Dr. Clarke on bridge funding

Dr Clarke gave a PowerPoint presentation that is appended to the minutes. In summary:

a. Research Support at GUMC consists of bridge funding (BGRO: $862K (does not incl. salary support), Lombardi: $2859,282 (incl. salary support), internal awards ($551K), PhD candidate support (~$1.5M), Toulmin endowment ($5M), MedStar gain share ($12.8M) and advancement (philanthropy) ($14M).

b. Decisions on bridge funding for the BGRO resided with Dr. Clarke in consultation with the Chair and finance, and for Lombardi with Dr. Weiner with the Executive Comm. And Sector leaders. In FY13, BGRO spent $355K for basic and $507K for clinical bridge funding. Lombardi spent $2.9M but this includes tenured faculty salaries, whereas BGRO does not. Conversion of Lombardi’s costs to BGRO costs was not available.

c. In FY13, internal awards amounted to $551K, part of which consisted of the Dean’s Pilot Project Awards of $250K. These funds were provided by the
Toulmin endowment, which generated $5M in FY13. It was not clear what the rest of the Toulmin endowment was used for.

d. In FY13, the MedStar gain share was $12.8M that was divided into a $6M quasi-endowment and $6.8M for distribution as $755K/yr for 9 yr. It was pointed out the $6M quasi endowment was in perpetuity, and it was recommended that this be continued for all future gain shares. However, it was not clear about the rationale for this distribution formula, although it likely resided with Chris Augostini and David Rubenstein. The MedStar gain share for FY14 is $22M.

e. There was a lot of discussion about how the FY14 MedStar gain share would be divvied up. It was recommended that the Financial Oversight Comm. should discuss how these funds are used. There was concern that the gain share would be used to “fill holes” rather than to invest in Chair and faculty recruitment. It was recommended that Dr. Danielsen write a letter to Dr. Federoff expressing the concern by the Caucus on this matter.

The meeting was adjourned at 1:40 pm

Attachment

Bridge funding presentation by Bob Clarke.